BetterLife Pharma Inc., an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, announced that findings from a study on its lead candidate BETR-001 (2-bromo-LSD) titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders” has been published in the peer-reviewed journal of Cell Report.

What do you think?

Psychedelics vs. SSRI's

March 9, 2023 Lynne Nardizzi

Here’s another look at the research showing that the superior ability of psychedelics to cross the nerve cell membranes might be one reason why they seem better at promoting cortical neuron growth than SSRIs.

5-MeO-DMT Update!

February 28, 2023 Lynne Nardizzi

Beckley Psytech receives FDA Investigational New Drug (IND) approval for Phase IIb study of BPL-003, a novel synthetic formulation of 5-MeO-DMT (Mebufotenin). This is big news!

Video on Psychedelics

February 11, 2023 Lynne Nardizzi

Can psychedelics cure? Psychedelics are unlocking new ways to treat conditions like addiction and depression. Click to watch!

Ketamine and the Brain

February 10, 2023 Lynne Nardizzi

New research shows how Ketamine acts as a “switch” in the brain.

Psychedelics and Brain Trauma

February 9, 2023 Lynne Nardizzi

Can psychedelics restore consciousness after brain trauma?

Researchers explore the potential of psychedelic therapies for people in minimally conscious states.

Psilocybin Mushrooms and Bipolar Disorder

February 4, 2023 Lynne Nardizzi

A new study published in the Journal of Psychopharmacology is the first to characterize the psychological impacts of psilocybin among people with bipolar disorder.

The findings indicate that many people with bipolar disorder who consume psilocybin, the primary psychoactive component of psychedelic “magic mushrooms,” believe that the experience is helpful. However, many also report adverse outcomes, such as manic symptoms.